HeartBeam, Inc. (NASDAQ:BEAT) reported a director purchase on April 16, 2026, when Branislav Vajdic acquired 31,250 shares of the company's common stock at $0.80 per share, for a total outlay of $25,000. Following the purchase, Vajdic's direct stake in the company increased to 909,914 shares.
The transaction occurred in connection with HeartBeam's underwritten public offering of 12,500,000 shares of common stock. The public offering was priced at $0.80 per share and closed with gross proceeds of $10 million. According to the terms disclosed, underwriters have a 30-day option to buy up to an additional 1,875,000 shares to cover any over-allotments.
Support for the offering included HeartBeam's first commercial customer, ClearCardio, as well as participation from company executives and institutional investors. Company statements indicate the funds are intended to support the rollout of HeartBeam's products.
Market context for the purchase is mixed. The stock was trading at $0.81 at the time the details were reported, and the share price has declined approximately 66% year-to-date. An InvestingPro analysis cited in disclosures flagged the stock as undervalued at current levels, and InvestingPro Tips noted that the relative strength index, or RSI, is in oversold territory; the tip service also references 11 additional exclusive tips available to subscribers.
On the research front, two firms have initiated coverage of HeartBeam in conjunction with recent capital-market activity. B. Riley started coverage with a Buy rating and assigned a $4.00 price target, highlighting HeartBeam's FDA-cleared device that generates a clinical-grade electrocardiogram. D. Boral Capital likewise initiated coverage with a Buy rating and set a $5.00 price target, citing the company's work on continuous cardiac monitoring technology.
Context and implications
The director purchase occurred alongside a material capital raise and the start of analyst coverage. The participation of a first commercial customer, company executives and institutional investors in the offering was disclosed as part of the $10 million financing round. The underwriters' over-allotment option provides flexibility to increase the share issuance if demand requires it.
What remains limited in public disclosures
- Details on specific deployment timelines for proceeds were not provided beyond the stated purpose of supporting product rollout.
- No additional operational metrics, such as revenue or commercialization milestones tied to the funds raised, were disclosed in the transaction notices.